Bluestar Genomics
Personalis to Distribute ClearNote Health's Epigenomic Cancer Detection Tech
The company said that ClearNote's platform, which is being used to develop cancer early detection assays, would complement its own offerings.
The firm has commercialized its pancreatic cancer test and has its sights set on an ovarian cancer test launching in 2023.
In Brief This Week: Thermo Fisher Scientific, Enzo Biochem, Codex DNA, More
News items for the week of Oct. 10, 2022.
Bluestar Genomics Gets CLIA Certification
The company said that the certification will enable it to perform its epigenomic pancreatic cancer test within its own laboratory.
Bluestar Genomics Sues Former Consultant, Ludwig Institute for Cancer Research Over IP Ownership
The complaint focuses on a recent patent filed by Chunxiao Song, the consultant, alleging that it falls within the terms of his contract with Bluestar.